Is hormone therapy safe?

What actually happened with the WHI.

In 2002, the Women's Health Initiative published results that sent shockwaves through medicine. The study appeared to show that hormone replacement therapy increased the risk of breast cancer, heart disease, stroke, and blood clots. Millions of women stopped their hormones overnight. Physicians stopped prescribing them. An entire generation of women suffered through menopause without treatment because of one study.

WHI materially changed understanding of hormone-therapy risk. The key insight from subsequent analysis is that age, timing, formulation, route, and whether a progestogen is required all matter. The original results were more complex than the headlines suggested, and the way they were communicated to the public created lasting confusion.

What the WHI actually found

The WHI enrolled women with an average age of 63 — well past the typical onset of menopause. Many participants had pre-existing cardiovascular risk factors. The study used a specific formulation (oral conjugated equine estrogen plus medroxyprogesterone acetate) that is no longer the preferred approach for most patients.

When researchers went back and analyzed the data by age group, the picture changed dramatically:

• Timing matters. For most healthy women with bothersome symptoms who begin hormone therapy before age 60 or within 10 years of menopause onset, major menopause societies consider the benefit-risk profile favorable when treatment is individualized.
• Women who started HRT after age 60, especially more than 10 years past menopause, did have increased cardiovascular risk — particularly with oral estrogen.
• The breast cancer risk was statistically significant but absolutely small: approximately 8 additional cases per 10,000 women per year in the combined estrogen-plus-progestin group. For women taking estrogen alone (without a uterus), breast cancer rates were actually lower than placebo.
• Transdermal estrogen (patches, gels) appears to have a lower risk of venous thromboembolism than oral estrogen and is often preferred when clotting risk is a consideration. The original study only tested oral formulations.

The medical community has spent two decades untangling this. The current consensus — supported by the Endocrine Society, the North American Menopause Society, and ACOG — is that hormone therapy is appropriate for symptomatic women who are within 10 years of menopause onset or under age 60, after an individualized risk-benefit assessment.

Who typically benefits.

Hormone therapy remains the most effective treatment for vasomotor symptoms (hot flashes, night sweats), and it can significantly improve sleep, mood, vaginal and urogenital health, bone density, and quality of life. For many women, the benefit is transformative.

The strongest candidates are:

• Women with moderate-to-severe vasomotor symptoms
• Women within 10 years of menopause onset or under 60
• Women without contraindications (see below)
• Women with premature ovarian insufficiency or early menopause, where hormone therapy is generally recommended until approximately the usual age of natural menopause unless contraindicated

Who should be cautious or avoid it.

There are clear contraindications. Hormone therapy is generally not appropriate for women with:

• Active or recent breast cancer (estrogen receptor-positive breast cancer is the primary concern)
• History of blood clots (DVT or pulmonary embolism) — though transdermal estrogen appears to have a lower risk of VTE than oral and may be considered in select cases with careful discussion
• Active liver disease
• Unexplained vaginal bleeding (until evaluated)
• History of stroke or heart attack
• Known clotting disorders (Factor V Leiden, etc.) — transdermal route may be considered with careful discussion

For women with a strong family history of breast cancer but no personal history, the conversation is more nuanced. The absolute risk increase from HRT is small, and for many women, the quality-of-life benefits outweigh the marginal increase in risk. But this is an individualized discussion, not a blanket recommendation.

How I think about this with patients.

I don't have a default position on HRT. I have a process.

First, I assess whether the patient's symptoms are severe enough that treatment is likely to meaningfully improve her quality of life. Mild symptoms may respond to lifestyle modifications. Moderate-to-severe symptoms that affect sleep, work, relationships, or daily function are a strong indication for treatment.

Second, I evaluate risk factors: age, time since menopause, cardiovascular history, breast cancer risk, clotting risk, family history. This isn't a simple yes/no checklist — it's a conversation about absolute risk, relative risk, and what matters to the individual patient.

Third, I choose the lowest effective dose of the safest appropriate formulation. For most patients, that means transdermal estrogen (patch or gel) rather than oral, and micronized progesterone rather than synthetic progestins — because the evidence suggests these carry lower risk profiles.

Fourth, I monitor. Regular follow-up, symptom assessment, and periodic re-evaluation of whether therapy should continue, be adjusted, or be tapered. HRT is not a set-it-and-forget-it prescription.

What I'd tell a friend.

If a friend asked me whether she should take hormone therapy for menopause, I'd say: find a physician who will actually sit with you, take a thorough history, assess your risk factors, discuss the evidence honestly, and help you make an informed decision. Not someone who says "it's too risky" based on a 20-year-old headline. Not someone who prescribes it without evaluation because you want it. Someone who treats it like what it is: a meaningful medical decision that deserves a thoughtful physician.

References.

• The Menopause Society (formerly NAMS). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials. JAMA. 2013;310(13):1353-1368.
• American College of Obstetricians and Gynecologists. Practice Bulletin No. 141: Management of Menopausal Symptoms. Obstet Gynecol. 2014 (reaffirmed 2023).